WSJ: Actavis nears acquisition of Forest Labs for up to $25B

Actavis (ACT) is in advanced negotiations to buy fellow pharmaceuticals provider Forest Laboratories (FRX) for up to $25B, the WSJ reports, adding that the deal could be announced today.

The figure is above Forest's market cap of $19.3B at the close of trade on Friday and compares with Actavis' $33.4B.

The acquisition would add to Actavis' recent purchase of Warner Chilcott and follow Forest's agreement in January to buy specialty-pharmaceutical company Aptalis Holdings.

One reason for the tie-up is to allow the companies to better negotiate with customers amid consolidation between U.S. Hospitals, insurers and doctors.

Carl Icahn could be set to benefit from the deal after he built up an 11.4% stake in Forest and successfully agitated for change in a bruising battle with the company's then management.

From other sites
Comments (1)
  • chummybeagle
    , contributor
    Comments (120) | Send Message
    Say what you will about Icahn, the guy knows how to invest in large-cap tech and healthcare with a seemingly value approach. Impressive.
    18 Feb 2014, 02:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs